AmericanJournalofHematology

The American Journal of Hematology is a leading international peer reviewed journal of hematology. @WileyGlobal. IF 12.8
Content edited by @evemariecrane

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Check out this excellent review on the role of alloBMT in aplastic anemia | @AjHematology

This is a timely and comprehensive review summarizing the most recent evidence 🙌🏽

Great writing as always, @Haemophage

https://t.co/rsNGMfMB1a

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Link to article in @AjHematology, also adding other co-authors including @bhemato @DarrenPanMD and more.

Lots of nuances in text around recommendations above, e.g. post-ASCT maintenance and what we'd actually recommend for our own patients (and why).

https://t.co/0kQYmMWtz3

[Hagop Kantarjian,MD @DrHKantarjian]

The chemotherapy-free regimen blinatumomab and ponatinib is associated with significantly improved PFS and OS compared to Hyper-CVAD with ponatinib, with less non-relapse morality and a reduced reliance on allo-SCT in Ph+ ALL.
https://t.co/gBXFBRrd0d

@AjHematology @UTMDAnderson

[Hagop Kantarjian,MD @DrHKantarjian]

Triple- nucleosides plus venetoclax result in outstanding outcomes in older #AML

https://t.co/sIawuDmsAR

@AjHematology @UTMDAnderson

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Pretty neat @AjHematology article!

By now, those who follow myeloma field know that we differentiate true EMD vs paraskeletal (PS) dz.

But: if PS plasmacytomas at Dx, >2x relative risk of true EMD later in #MMsm journey vs if not...
Causation or function of tumor bio unclear.

[Sankalp Arora, MD @sankalparoraMD]

Out in @AjHematology.
Obesity, TP53 VAF of 45% or more and WBC>50,000 are key risk factors for relapse after frontline blinatumomab based therapy in Ph-neg B-ALL. Post relapse outcomes are dismal, with a median OS of 7 months.

https://t.co/R79s5JHE6q

@jayastuMD @DrHKantarjian

[AmericanJournalofHematology @AjHematology]

New real-world data on #Gilteritinib in relapsed/refractory #FLT3-mutated #AML: treatment beyond 2nd line remains effective and enables transplant in selected patients. Study of 171 cases across 4 countries. #Leukemia #Hematology
https://t.co/PwhP16bklB @jadothm

[AmericanJournalofHematology @AjHematology]

Congratulations to Dr. Mahmoud Mikda, the recipient of the 2025 American Journal of Hematology Young Investigator Award for the paper entitled:
Sialyl-T Antigen: A Novel Red Blood Cell Determinant for Plasmodium falciparum Invasion https://t.co/ECGISHIkpX #ASH25

[Vera Ghali, MD @veraghali]

A study finds increased use of prescription drugs such as treatments for anemia like iron supplements, Vit. B12, and folic acid, and antibiotics for recurrent infections 18 months before diagnosis of some indolent hematologic malignancies whose symptoms mimic benign medical conditions. The findings underline the necessity for increasing awareness for markers of hematologic malignancies in primary care to avoid unnecessary delays in diagnosis and treatment and to avoid the increased risk of morbidity.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

🎵 Should I stay or should I go? [on BCMA bispecifics]

Thanks @AjHematology for featuring US #MMsm Consortium work.

Delayed responses most likely if MR by D30 (i.e., on way to ≥PR) or if SD but not lymphopenic. If so, continued bsAb therapy may be more worth the infxn risks!

[AmericanJournalofHematology @AjHematology]

Airborne pollutants are elevated in the Bronx, New York and correlate with worse #MDS outcomes. Exposure to similar pollutants leads to inflammation in vivo.
https://t.co/HZYygljuO3
@MeghaVerma83142 @montefiorenyc @einsteinmed @aditishasMD

[AmericanJournalofHematology @AjHematology]

Despite promising phase-2 results, phase-3 Sickle Cell Disease (SCD) pain trials failed to meet clinical endpoints. We show time-to-crisis-resolution is influenced by site, prior ED use and surgery history. It’s time to redefine outcomes in SCD-VOE trials.
https://t.co/VLboiWFRBP

[AmericanJournalofHematology @AjHematology]

A multi-center prospective cohort study on the use of weight-adjusted dalteparin in patients over 90 kg with acute cancer-associated venous thromboembolism – the WAVe study #hematology #thrombosis
https://t.co/aVUcd2kir5
@TzufeiWang @MarcCarrier1 @DebSiegal @DellucAurelien

[AmericanJournalofHematology @AjHematology]

A marked difference in post-transplant survival was linked to platelet counts. Thrombocytopenia was more frequent after CBT (39%) than unrelated BMT (17%) on day 50. By day 100, both groups had similar rates (11%), suggesting the disparity was transient. https://t.co/AnMuMBRg0W

[AmericanJournalofHematology @AjHematology]

Large multicenter retrospective analysis indicating that the incorporation of caplacizumab into treatment of immune TTP in the ICU improves the ICU survival. Overall ICU survival was high.
https://t.co/8ECi2dDxST
@Ralph_Wendt @LinusAlexanderV @oncologne @UKKoeln

[AmericanJournalofHematology @AjHematology]

New study of 90K exomes reveals population-based prevalence, penetrance, and clinical impact of MDS- and CHIP-associated gene variants—including novel germline RUNX1 mutations. Findings support early monitoring. #Genomics #MDS #CHIP #HemeOnc
https://t.co/2bc5QroDU3 @ImanSarami

[AmericanJournalofHematology @AjHematology]

For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology.
https://t.co/aV2rpKDtgI
@AlGarfall

[Mostafa Faisal @MostafaFaisal14]

Efficacy of the VIALE-A Regimen for AML With Monocytic Differentiation as Determined by French-American-British Subtyping and Gene Expression Profiling @AjHematology
https://t.co/dtSsLdTDiR

[Mostafa Faisal @MostafaFaisal14]

Mixed-Phenotype Acute Leukemia With Mutated TP53: Genetic Landscape, Therapeutic Response, and Outcomes @AjHematology
https://t.co/GxGUz3hWbb